NCT04081259View on ClinicalTrials.gov

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

August 3, 2023

Study Completion Date

August 26, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

LY3214996

LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04081259 - LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | Biotech Hunter | Biotech Hunter